Beneficial	O
effects	O
of	O
voglibose	B:C0532578
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
via	O
gastrointestinal	O
bile	O
acid	I:C0005390
modification	O
.	O

Beneficial	O
effects	O
of	O
voglibose	O
administration	B:C1533734
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
via	O
gastrointestinal	O
bile	O
acid	I:C0005390
modification	O
.	O

Beneficial	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	B:C0598783
metabolism	I:C0598783
via	O
gastrointestinal	O
bile	O
acid	I:C0005390
modification	O
.	O

Beneficial	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
via	O
gastrointestinal	B:C0012240
bile	O
acid	I:C0005390
modification	O
.	O

Beneficial	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
via	O
gastrointestinal	O
bile	B:C0005390
acid	I:C0005390
modification	O
.	O

This	O
study	B:C0008972
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	O
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	O
mice	I:C0025933
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	B:C0018017
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	O
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	O
mice	I:C0025933
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	B:C0532578
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	O
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	O
mice	I:C0025933
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	B:C1533734
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	O
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	O
mice	I:C0025933
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	B:C0598783
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	O
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	O
mice	I:C0025933
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	B:C0521974
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	O
mice	I:C0025933
.	O

This	O
study	O
was	O
designed	O
with	O
the	O
goal	O
of	O
examining	O
the	O
effects	O
of	O
voglibose	O
administration	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
and	O
underlying	O
mechanism	O
high	O
fat	I:C0521974
diet	I:C0521974
-	O
induced	O
obese	B:C0025933
mice	I:C0025933
.	O

Male	O
C57BL	B:C1521751
/	I:C1521751
6	I:C1521751
mice	I:C1521751
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	O
:	O
a	O
control	O
diet	O
(	O
CTL	O
)	O
,	O
high	O
-	O
fat	O
diet	O
(	O
HF	O
)	O
,	O
high	O
-	O
fat	O
diet	O
supplemented	O
with	O
voglibose	O
(	O
VO	O
)	O
,	O
and	O
high	O
fat	O
diet	O
pair	O
-	O
fed	O
group	O
(	O
PF	O
)	O
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	B:C0428462
lipid	I:C0428462
and	O
glucose	O
levels	I:C0583332
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	O
and	O
bile	O
acid	I:C0678714
metabolism	I:C0678714
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	O
lipid	I:C0428462
and	O
glucose	B:C0583332
levels	I:C0583332
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	O
and	O
bile	O
acid	I:C0678714
metabolism	I:C0678714
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	O
lipid	I:C0428462
and	O
glucose	O
levels	I:C0583332
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	B:C0017337
involved	O
in	O
lipid	O
and	O
bile	O
acid	I:C0678714
metabolism	I:C0678714
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	O
lipid	I:C0428462
and	O
glucose	O
levels	I:C0583332
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	B:C0598783
and	O
bile	O
acid	I:C0678714
metabolism	I:C0678714
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	O
lipid	I:C0428462
and	O
glucose	O
levels	I:C0583332
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	O
involved	O
in	O
lipid	O
and	O
bile	B:C0678714
acid	I:C0678714
metabolism	I:C0678714
.	O

In	O
addition	O
,	O
pyrosequencing	B:C2732543
was	O
used	O
to	O
analyze	O
the	O
composition	O
of	O
gut	O
microbiota	O
found	O
in	O
feces	O
.	O

In	O
addition	O
,	O
pyrosequencing	O
was	O
used	O
to	O
analyze	O
the	O
composition	B:C0486616
of	O
gut	O
microbiota	O
found	O
in	O
feces	O
.	O

In	O
addition	O
,	O
pyrosequencing	O
was	O
used	O
to	O
analyze	O
the	O
composition	O
of	O
gut	O
microbiota	O
found	O
in	O
feces	B:C0015733
.	O

Total	B:C0043094
body	I:C0043094
weight	I:C0043094
gain	I:C0043094
was	O
significantly	O
lower	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
CTL	O
,	O
HF	O
,	O
and	O
PF	O
groups	O
.	O

The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	B:C3853758
profiles	I:C3853758
including	O
those	O
of	O
blood	O
glucose	I:C0392201
,	O
triglyceride	O
,	O
and	O
total	O
cholesterol	I:C0428466
levels	I:C0428466
.	O

The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	O
profiles	I:C3853758
including	O
those	O
of	O
blood	B:C0392201
glucose	I:C0392201
,	O
triglyceride	O
,	O
and	O
total	O
cholesterol	I:C0428466
levels	I:C0428466
.	O

The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	O
profiles	I:C3853758
including	O
those	O
of	O
blood	O
glucose	I:C0392201
,	O
triglyceride	B:C0428475
,	O
and	O
total	O
cholesterol	I:C0428466
levels	I:C0428466
.	O

The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	O
profiles	I:C3853758
including	O
those	O
of	O
blood	O
glucose	I:C0392201
,	O
triglyceride	O
,	O
and	O
total	B:C0428466
cholesterol	I:C0428466
levels	I:C0428466
.	O

The	O
12	O
-	O
week	O
voglibose	B:C0532578
administration	O
decreased	O
the	O
ratio	O
of	O
Firmicutes	O
to	O
Bacteroidetes	O
found	O
in	O
feces	O
.	O

The	O
12	O
-	O
week	O
voglibose	O
administration	B:C1533734
decreased	O
the	O
ratio	O
of	O
Firmicutes	O
to	O
Bacteroidetes	O
found	O
in	O
feces	O
.	O

The	O
12	O
-	O
week	O
voglibose	O
administration	O
decreased	O
the	O
ratio	O
of	O
Firmicutes	B:C1254144
to	O
Bacteroidetes	O
found	O
in	O
feces	O
.	O

The	O
12	O
-	O
week	O
voglibose	O
administration	O
decreased	O
the	O
ratio	O
of	O
Firmicutes	O
to	O
Bacteroidetes	B:C0995456
found	O
in	O
feces	O
.	O

The	O
12	O
-	O
week	O
voglibose	O
administration	O
decreased	O
the	O
ratio	O
of	O
Firmicutes	O
to	O
Bacteroidetes	O
found	O
in	O
feces	B:C0015733
.	O

Circulating	O
levels	O
of	O
taurocholic	B:C0039358
and	O
cholic	O
acid	I:C0055568
were	O
significantly	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
and	O
CTL	O
groups	O
.	O

Circulating	O
levels	O
of	O
taurocholic	O
and	O
cholic	B:C0055568
acid	I:C0055568
were	O
significantly	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
and	O
CTL	O
groups	O
.	O

Deoxycholic	B:C0011479
acid	I:C0011479
levels	O
tended	O
to	O
be	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
group	O
.	O

Voglibose	B:C0532578
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	B:C1533734
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
downregulated	B:C0013081
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	B:C1413895
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	B:C1415629
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	B:C0041904
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	B:C1418779
,	O
whereas	O
FXRα	O
was	O
not	O
affected	O
.	O

Voglibose	O
administration	O
downregulated	O
expression	O
levels	O
of	O
CYP8B1	O
and	O
HNF4α	O
genes	I:C1415629
and	O
upregulated	O
those	O
of	O
PGC1α	O
,	O
whereas	O
FXRα	B:C1417825
was	O
not	O
affected	O
.	O

Voglibose	B:C0532578
administration	O
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	O
metabolites	I:C0870883
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
in	O
mice	O
.	O

Voglibose	O
administration	B:C1533734
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	O
metabolites	I:C0870883
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
in	O
mice	O
.	O

Voglibose	O
administration	O
elicits	O
changes	O
in	O
the	O
composition	B:C0486616
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	O
metabolites	I:C0870883
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
in	O
mice	O
.	O

Voglibose	O
administration	O
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	B:C0870883
metabolites	I:C0870883
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
in	O
mice	O
.	O

Voglibose	O
administration	O
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	O
metabolites	I:C0870883
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	B:C0598783
metabolism	I:C0598783
in	O
mice	O
.	O

Voglibose	O
administration	O
elicits	O
changes	O
in	O
the	O
composition	O
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	O
metabolites	I:C0870883
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	O
metabolism	I:C0598783
in	O
mice	B:C0025929
.	O

